Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
This can be more convenient for both patients and healthcare providers
The Phase IIb oral trial administered doses well above the typical subcutaneous research dose for 24 weeks without serious adverse events attributable to the peptide [6]
Known and theoretical safety concerns include: Retatrutide (and the GLP-1 receptor agonist class): Nausea, vomiting, diarrhoea, and reduced appetite are the most commonly reported side effects
No human diabetes-treatment evidence was identified
This dose falls within the effective clinical range while allowing room to increase if response is minimal
US$ 25.08
US$ 20.16
US$ 29.96
US$ 26.95
